These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 12417542

  • 1. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN, Valsartan Heart Failure Trial Investigators.
    Circulation; 2002 Nov 05; 106(19):2454-8. PubMed ID: 12417542
    [Abstract] [Full Text] [Related]

  • 2. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
    Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators.
    Circulation; 2003 Mar 11; 107(9):1278-83. PubMed ID: 12628948
    [Abstract] [Full Text] [Related]

  • 3. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, Val-HeFT Investigators (Valsartan Heart Failure Trial).
    J Am Coll Cardiol; 2002 Oct 16; 40(8):1414-21. PubMed ID: 12392830
    [Abstract] [Full Text] [Related]

  • 4. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.
    Ter Arkh; 2006 Oct 16; 78(8):14-20. PubMed ID: 17078211
    [Abstract] [Full Text] [Related]

  • 5. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.
    Am Heart J; 2004 Dec 16; 148(6):951-7. PubMed ID: 15632877
    [Abstract] [Full Text] [Related]

  • 6. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Mareev VIu, Belenkov IuN.
    Ter Arkh; 2005 Dec 16; 77(8):34-43. PubMed ID: 16206603
    [Abstract] [Full Text] [Related]

  • 7. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
    Cohn JN, Tognoni G, Glazer R, Spormann D.
    Eur J Heart Fail; 2000 Dec 16; 2(4):439-46. PubMed ID: 11113722
    [Abstract] [Full Text] [Related]

  • 8. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.
    Ter Arkh; 2006 Dec 16; 78(9):61-71. PubMed ID: 17076227
    [Abstract] [Full Text] [Related]

  • 9. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul 16; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 10. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN.
    Circulation; 1999 May 25; 99(20):2658-64. PubMed ID: 10338459
    [Abstract] [Full Text] [Related]

  • 11. Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    Cohn JN.
    Am J Cardiol; 2002 Nov 01; 90(9):992-3. PubMed ID: 12398968
    [No Abstract] [Full Text] [Related]

  • 12. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN, Val-HeFT Heart Failure Trial Investigators.
    J Am Coll Cardiol; 2002 Sep 04; 40(5):970-5. PubMed ID: 12225725
    [Abstract] [Full Text] [Related]

  • 13. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, Valsartan Heart Failure Trial Investigators.
    Circulation; 2003 Sep 16; 108(11):1306-9. PubMed ID: 12939207
    [Abstract] [Full Text] [Related]

  • 14. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun 16; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 15. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB, Schlosshan D, Williams SG.
    Int J Clin Pract; 2004 Feb 16; 58(2):184-91. PubMed ID: 15055867
    [Abstract] [Full Text] [Related]

  • 16. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
    Majani G, Giardini A, Opasich C, Glazer R, Hester A, Tognoni G, Cohn JN, Tavazzi L.
    J Card Fail; 2005 May 16; 11(4):253-9. PubMed ID: 15880333
    [Abstract] [Full Text] [Related]

  • 17. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
    Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C.
    Eur J Heart Fail; 2013 Nov 16; 15(11):1236-44. PubMed ID: 23787721
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
    Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M.
    Heart; 2006 May 16; 92(5):625-30. PubMed ID: 16159967
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 20. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.